CDXS - Codexis, Inc.
| Previous Close | 15.60 |
| Open | 15.61 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1800 |
| Day's Range | 15.48 - 15.74 |
| 52 Week Range | 12.68 - 22.49 |
| Volume | 224,771 |
| Avg. Volume | 317,668 |
| Market Cap | 918M |
| Beta (3Y Monthly) | -0.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.21 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.50 |
- GlobeNewswire
Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir
Codexis, Inc. (CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the prestigious peer-reviewed journal Science, detailing the development of a novel, highly efficient enzymatic cascade for the production of Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The publication (https://science.sciencemag.org/content/366/6470/1255) describes the optimization, using Codexis’ proprietary CodeEvolver® protein engineering platform, of five enzymes for the synchronized synthesis of a complex pharmaceutical candidate in very few steps, starting from simple raw materials. Merck and Codexis collaborated on the engineering of the enzymes to enable the efficient synthesis of the Active Pharmaceutical Ingredient (API).
- Simply Wall St.
Codexis (NASDAQ:CDXS) Shareholders Have Enjoyed A Whopping 567% Share Price Gain
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...
- Thomson Reuters StreetEvents
Edited Transcript of CDXS earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Codexis Inc Earnings Call
- Zacks
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Zacks
Codexis (CDXS) Q3 Earnings and Revenues Beat Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 166.67% and 32.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Codexis Reports Third Quarter 2019 Financial Results
Total revenues rose 29% to $21.9 million driven by strength in R&D, product, and CodeEvolver® licensing revenues Eleven customers each contributed at least a quarter.
- GlobeNewswire
Codexis to Participate in Four Investment Conferences in November
REDWOOD CITY, Calif., Nov. 05, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in four upcoming.
- GlobeNewswire
Codexis to Hold Third Quarter 2019 Conference Call on November 5
REDWOOD CITY, Calif., Oct. 29, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2019 financial results.
- Insider Monkey
Is Codexis, Inc. (CDXS) A Good Stock To Buy ?
How do we determine whether Codexis, Inc. (NASDAQ:CDXS) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
- Simply Wall St.
A Look At The Fair Value Of Codexis, Inc. (NASDAQ:CDXS)
How far off is Codexis, Inc. (NASDAQ:CDXS) from its intrinsic value? Using the most recent financial data, we'll take...
- GlobeNewswire
Codexis’ Protein Engineering Forum Highlights Progress and Future Direction of the Field
Codexis, Inc. (CDXS), a leading protein engineering company, assembled approximately 150 top scientists in protein engineering to discuss recent progress and future direction in a forum held last week in Palo Alto, Calif. Speakers highlighted recent successes in enzymatic manufacturing, biologics discovery, and agricultural and diagnostic applications, as well as technical progress in library generation, high-throughput screening, and bioinformatics. The keynote address by Nobel Laureate Dr. Frances H. Arnold illuminated the audience on the history of the field and highlighted the promise of protein engineering technology.
- GlobeNewswire
Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 26, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor.
- Simply Wall St.
Is Codexis, Inc.'s (NASDAQ:CDXS) CEO Pay Justified?
John Nicols became the CEO of Codexis, Inc. (NASDAQ:CDXS) in 2012. First, this article will compare CEO compensation...
- Motley Fool
3 Top Stocks Under $20
Your money can buy more shares of these promising companies thanks to an affordable stock price.
- GuruFocus.com
Codexis Inc (CDXS) President and CEO John J Nicols Bought $133,000 of Shares
President and CEO of Codexis Inc (30-Year Financial, Insider Trades) John J Nicols (insider trades) bought 10,000 shares of CDXS on 08/20/2019 at an average price of $13.3 a share. Continue reading...
- Thomson Reuters StreetEvents
Edited Transcript of CDXS earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Codexis Inc Earnings Call
- Motley Fool
Codexis Rolls Into Second Half Armed with Cash
The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?
Motley FoolCodexis(CDXS) Q2 2019 Earnings Call Transcript
CDXS earnings call for the period ending June 30, 2019.
- Zacks
Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -100.00% and -17.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Codexis Reports Second Quarter 2019 Financial Results
Product revenue up 68%; R&D revenue spread over wider base of customers and markets Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif., Aug. 06,.
- GlobeNewswire
Codexis to Hold Second Quarter 2019 Conference Call on August 6
REDWOOD CITY, Calif., July 30, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results.
- GlobeNewswire
Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives
Codexis, Inc. (CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement. “The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets,” said Codexis President and CEO John Nicols.
- Motley Fool
Is Codexis a Buy?
The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.
